Accrol Group Holdings PLC Board Changes (9350X)

TIDMACRL

RNS Number : 9350X

Accrol Group Holdings PLC

02 May 2023

2 May 2023

Accrol Group Holdings plc

("Accrol, the "Group" or the "Company")

(AIM: ACRL)

Board Changes

Appointment of new Chief Financial Officer

Accrol, the UK's leading independent tissue converter, is pleased to announce that Chris Welsh has today joined the Board as Chief Financial Officer ("CFO").

As detailed in the HY23 Results announcement, Chris succeeds Richard Newman, who has now resigned as CFO and stepped down from the Board but, to ensure a smooth transition, has agreed to remain with the Company until the FY23 audit process is completed and the Final Results are released.

Chris joined the business in October 2022, as part of the Board's succession planning. Before his move to Accrol, Chris held several senior finance roles at the multinational chemical manufacturing group, Ineos, most latterly as Head of Financial Reporting at the Enterprises Division.

Chris is a Chartered Accountant, who qualified with PwC in 2015.

Gareth Jenkins, Chief Executive Officer, said:

"We are delighted to welcome Chris to the Board. Since joining Accrol last year, he has been operating at the highest standard, demonstrating the commitment, energy and acumen which will help deliver our strategic objectives.

"I would also like to take this opportunity to thank Richard for his significant contribution to the Group. On appointment, he was tasked with transforming the finance function of the business, which he has achieved. Richard hands over to Chris a much strengthened finance team and infrastructure, capable of serving a much larger business."

Further information relating to Christopher Welsh

In accordance with Schedule 2(g) of the AIM rules, Christopher ("Chris") James Welsh (aged 33) holds or has held in the past five years the following directorships:

Current directorships

 
 --   Accrol UK Limited 
 --   LTC Parent Ltd 
 --   John Dale Holdings Limited 
 --   Leicester Tissue Company Limited 
 --   Art Tissue Ltd 
 --   Accrol Papers Limited 
 --   Accrol Holdings Limited 
 --   John Dale Limited 
 

Chris holds no shares in the Company.

There is no further information on Chris required to be disclosed under Schedule Two, paragraph (g) (i)-(viii) of the AIM Rules for Companies.

 
For further information, please 
 contact: 
 
Accrol Group Holdings plc 
Dan Wright, Executive Chairman           Via Belvedere Communications 
Gareth Jenkins, Chief Executive Officer 
Chris Welsh, Chief Financial Officer 
 
Zeus (Nominated Adviser & Broker) 
Dan Bate / Jordan Warburton                 Tel: [phone] 
Dominic King                                Tel: [phone] 
 
Shore Capital Stockbrokers (Joint           Tel: [phone] 
 Broker) 
Malachy McEntyre / Mark Percy / James 
 Thomas 
 
Belvedere Communications Limited 
Cat Valentine                               Tel: [phone] 
Keeley Clarke                               Tel: [phone] 
                                             [e-mail] 
 

Overview of Accrol

Accrol Group Holdings plc is a leading tissue converter and supplier of toilet tissues, kitchen rolls, facial tissues, and wet wipes to many of the UK's leading discounters and grocery retailers across the UK. The Group now operates from six manufacturing sites, including four in Lancashire, which together supply c.21.5% (volume) of the UK tissue market valued at cGBP2.5bn at retail sales value.

For more information, please visit www.accrol.co.uk .

Link for Accrol Today video: https://www.accrol.co.uk/our-business/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAUWOSROSUSUAR

(END) Dow Jones Newswires

May 02, 2023 02:00 ET (06:00 GMT)